Body Protection Compound-157. A synthetic peptide studied for its role in tissue repair, gut healing, and injury recovery. One of the most extensively researched repair peptides.

Thymosin Beta-4 fragment. Studied for angiogenesis, cell migration, and inflammatory modulation. Often researched alongside BPC-157 for synergistic tissue repair effects.

Copper tripeptide-1. Studied for skin repair, anti-inflammatory effects, and collagen synthesis. Naturally occurring in human plasma; declines significantly with age.

Tripeptide Lys-Pro-Val. A melanocortin receptor agonist studied for anti-inflammatory and gut-protective effects. Derived from alpha-MSH.

Szeto-Schiller peptide 31. Targets the inner mitochondrial membrane, studied for cardioprotection, mitochondrial dysfunction, and age-related decline.

Tetrapeptide Ala-Glu-Asp-Gly. Studied for telomerase activation, melatonin regulation, and longevity-related gene expression. Developed by the St. Petersburg Institute of Bioregulation.

Mitochondrial ORF of the 12S rRNA type-c. A mitochondria-derived peptide that activates AMPK, regulates metabolic homeostasis, and is studied in metabolic syndrome and aging.

Nicotinamide Adenine Dinucleotide. Central coenzyme in cellular energy metabolism. Research focuses on declining NAD+ levels with aging and implications for mitochondrial function and longevity signaling (sirtuins, PARP).

Triple GIP/GLP-1/glucagon receptor agonist (LY3437943). In Phase 3 trials at Eli Lilly. Research focuses on weight loss, metabolic health, and cardiometabolic outcomes.

Selective GH secretagogue and ghrelin receptor agonist. Studied for growth hormone release, lean mass preservation, and minimal cortisol/prolactin impact compared to earlier GHRPs.

GHRH analogue. Available with DAC (longer acting, weekly dosing) and without DAC (shorter pulse pattern). Studied for GH/IGF-1 elevation and lean body composition.

FDA-approved GHRH analogue (Egrifta) for HIV-associated lipodystrophy. Studied for visceral fat reduction, IGF-1 elevation, and cognitive function in aging populations.

ACTH(4-7) analogue developed in Russia. Studied for BDNF upregulation, neuroprotection, and cognitive enhancement. Used clinically in Russia and Ukraine for stroke and cognitive impairment.

Tuftsin analogue developed by the Institute of Molecular Genetics in Russia. Studied for anxiolytic effects, immune modulation, and GABA receptor activity without sedation or dependence.

Melanocortin receptor agonist. FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Studied for sexual dysfunction in both sexes via central nervous system action.

Human Chorionic Gonadotropin. Glycoprotein hormone studied for LH-receptor agonism, testosterone production support, and fertility applications in both male and female research models.

Immunomodulatory peptide derived from thymosin fraction 5. Approved in 37 countries (Zadaxin). Studied for T-cell maturation, innate immune activation, and adjuvant therapy in infectious and oncological research.